Description
Expanding knowledge on genetic and epigenetic risk factors is rapidly enhancing our understanding of the complex molecular interactions and systems involved in the pathogenesis of Alzheimer’s disease. In this publication, leading experts discuss emerging novel conceptual models of the disease along with advances in the development of surrogate markers that will not only improve the accuracy of diagnostic technologies but also improve the prospects of developing disease-modifying interventions. The novel framework of the disease presented here highlights research on biological markers as well as efforts to validate technologies for early and accurate detection. It also introduces notion of a complex systems dysfunction that extends beyond prevailing ideas derived from the ‘amyloid’ or ‘tau’ hypotheses.This outstanding publication provides researchers, clinicians, students and other professionals interested in neurodegenerative disorders with a comprehensive update on current trends and future directions in therapy development, with special focus on advances in clinical trial designs.
Chapter
Role of Biomarkers in Diagnosing and Treating Alzheimer’s Disease
Treating Alzheimer’s Disease
Is Prevention a Realistic Goal?
The Genetics of Alzheimer’s Disease
Early Family Studies of Alzheimer’s Disease
Amyloid Precursor Protein
Early Linkage and Candidate Studies of Late-Onset Alzheimer’s Disease
Sortilin-Related Receptor-1
Angiotensin Converting Enzyme
Genome-Wide Association Studies and Consortia Efforts
Pathways Consistently Implicated in AD Risk
Conclusions and Future Directions of Genetic Research
Current Conceptual View of Alzheimer’s Disease
Current Theories of Alzheimer’s Disease
Neuropathological Basis of Alzheimer’s Disease and Alzheimer’s Disease Diagnosis
Historical Perspective: Role of Clinical-Pathologic Studies of Alzheimer’s Disease
Overview of the Neuropathology of Alzheimer’s Disease
Current Diagnostic Criteria for the Neuropathologic Diagnosis of Alzheimer’s Disease
Recent Advances and New Perspectives
New Directions in Clinical Criteria and Influence on Pathologic Criteria
Biomarkers and Their Relationship with Alzheimer’s Disease Pathology
Diagnostic Tools: Fluid Biomarkers for Alzheimer’s Disease
Biomarkers for AD Pathology
Biomarkers to Identify Pathological Processes Not Typical of AD
Standardization of CSF Biomarkers for AD
MRI- and PET- Based Imaging Markers for the Diagnosis of Alzheimer’s Disease
Resting State Functional Connectivity
Positron Emission Tomography
Multicenter Imaging Studies
Which Imaging Marker to Use – A Clinical Perspective
Changing Diagnostic Concepts of Alzheimer’s Disease
Clinical Criteria for the Dementia of Alzheimer’s Disease
Clinical Criteria for Mild Cognitive Impairment due to Alzheimer’s Disease
Research Criteria for Preclinical Alzheimer’s Disease
Comparison of NIA-AA Criteria with Other Diagnostic Frameworks
Pharmacological Treatment of Alzheimer’s Disease
Part 1: Current Treatments
Part 2: Prevention Trials
Part 3: Current Treatment Development
Regulatory Requirements on Clinical Trials in Alzheimer’s Disease
Diagnostic Criteria of Alzheimer’s Disease
Regulatory Perspectives on the Use of Biomarkers
Conclusion and Consequences for Regulators
Perspectives on Alzheimer’s Disease: Past, Present and Future
Quandary of Alzheimer’s Disease: Prototype Problem for a Grand Global Challenge
The Longevity Revolution – Pending Calamity in Healthcare- Economic
Alzheimer’s Disease: A Model for Solving Healthcare Challenges
Grand Global Challenge – Prevent Alzheimer by 2020
Prevention: A Strategic Goal for Healthcare Crisis
Exploring New Conceptual Models of Dementia
‘Systems Failure’ – A Different Paradigm for Alzheimer’s Disease
Alzheimer's Disease - Modernizing Concept, Biological Diagnosis and Therapy
( Advances in Biological Psychiatry )
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
